Abstract
It is still a tremendous challenge to combat multidrug resistant (MDR) cancer up to now, due to cancer resistance to chemotherapeutic agents. Herein, we put a new strategy for effective treatment of MDR cancer by improving chemotherapeutic efficacy via chemosensitizer in combination with phototherapy. Our previous work has demonstrated poly (ethylene glycol) - poly (curcumin-dithiodipropionic acid) (PEG-PCDA) is a good pre-chemosensitizer and enhances the sensitivity of MDR cancer cells to doxorubicin (DOX). In this study, we firstly synthesized mesoporous carbon nanoparticles (MCNs) having excellent photothermal and photodynamic effects, which could load a high dose of hydrophobic drug and presented pH-responsive drug release characteristics. On this basis, we developed a multifunctional MCN based drug delivery system to take chemo/photo- co-therapy against MDR human breast cancer MCF-7/ADR cells. The MCN based drug delivery system loaded 36.4% DOX and was coated with 23.2% PEG-PCDA, which could take photothermal and photodynamic effects under near-infrared (NIR) irradiation and trigger drug release by pH, glutathione (GSH), and/or NIR irradiation, termed as PEG-PCDA/DOX@MCNs. Once the PEG-PCDA/DOX@MCNs had been delivered into MCF-7/ADR cells, DOX release was triggered by degradation of PEG-PCDA via GSH and weak acidic pH, and in combination with MCN yielded photothermal and photodynamic effects under NIR irradiation, PEG-PCDA/DOX@MCNs could reduce premature drug release and then enhance anti-MDR cancer efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.